Skip to main content

Table 2 Systemic inflammation parameters and their prognostic impact on overall survival

From: Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

Parameter n (%) Median OS, months HR (95% CI) p-valuea
NLR
 <  3 35 (49.3%) 7.8 1.934 (1.1–3.3) 0.014
 ≥ 3 36 (50.7%) 13.7
PLR
 <  200 40 (56.3%) 5.4 1.567 (0.9–2.7) 0.096
 ≥ 200 31 (43.7%) 13.0
Serum albumin levels
 <  3.6 g/dL 14 (19.4%) 4.9 2.142 (1.1–4.5) 0.040
 ≥ 3.6 g/dL 47 (65.3%) 12.4
 Unknown 11 (15.3%)
SIS
 0 25 (35.2%) 16.0 0.004
 1 18 (25.4%) 7.8
 2 21 (29.6%) 5.7
 3 7 (9.9) 4.0
SIS groups
 0 25 (35.2%) 16.0 0.475 (0.3–0.8) 0.008
 1–3 46 (64.8%) 7.3
  1. CI Confidence interval, HR Hazard ratio, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, SIS Systemic inflammation score
  2. aSignificant values are indicated in bold
\